These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

674 related items for PubMed ID: 35670067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).
    Seliger SL, de Lemos J, Neeland IJ, Christenson R, Gottdiener J, Drazner MH, Berry J, Sorkin J, deFilippi C.
    JACC Heart Fail; 2015 Jun; 3(6):445-455. PubMed ID: 25982111
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
    Pocock SJ, Ferreira JP, Gregson J, Anker SD, Butler J, Filippatos G, Gollop ND, Iwata T, Brueckmann M, Januzzi JL, Voors AA, Zannad F, Packer M.
    Eur Heart J; 2021 Nov 14; 42(43):4455-4464. PubMed ID: 34423361
    [Abstract] [Full Text] [Related]

  • 7. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.
    Packer M, Januzzi JL, Ferreira JP, Anker SD, Butler J, Filippatos G, Pocock SJ, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    Eur J Heart Fail; 2021 Sep 14; 23(9):1529-1538. PubMed ID: 34053177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF.
    Haller PM, Jarolim P, Palazzolo MG, Bellavia A, Antman EM, Eikelboom J, Granger CB, Harrington J, Healey JS, Hijazi Z, Patel MR, Patel SM, Ruff CT, Wallentin L, Braunwald E, Giugliano RP, Morrow DA.
    J Am Coll Cardiol; 2024 Oct 15; 84(16):1528-1540. PubMed ID: 39230543
    [Abstract] [Full Text] [Related]

  • 11. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in acute heart failure: Data from the ACE 2 study.
    Berge K, Lyngbakken MN, Myhre PL, Brynildsen J, Røysland R, Strand H, Christensen G, Høiseth AD, Omland T, Røsjø H.
    Clin Biochem; 2021 Feb 15; 88():30-36. PubMed ID: 33245872
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.
    Alehagen U, Dahlström U, Rehfeld JF, Goetze JP.
    Clin Chem; 2010 Nov 15; 56(11):1718-24. PubMed ID: 20844063
    [Abstract] [Full Text] [Related]

  • 14. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A.
    Am Heart J; 2012 May 15; 163(5):821-8. PubMed ID: 22607860
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study.
    Kim Y, Matsushita K, Sang Y, Grams ME, Skali H, Shah AM, Hoogeveen RC, Solomon SD, Ballantyne CM, Coresh J.
    Am J Kidney Dis; 2015 Apr 15; 65(4):550-8. PubMed ID: 25446023
    [Abstract] [Full Text] [Related]

  • 18. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
    Myhre PL, O'Meara E, Claggett BL, de Denus S, Jarolim P, Anand IS, Beldhuis IE, Fleg JL, Lewis E, Pitt B, Rouleau JL, Solomon SD, Pfeffer MA, Desai AS.
    Circ Heart Fail; 2018 Nov 15; 11(11):e005312. PubMed ID: 30571192
    [Abstract] [Full Text] [Related]

  • 19. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
    Murphy SP, Prescott MF, Maisel AS, Butler J, Piña IL, Felker GM, Ward JH, Williamson KM, Camacho A, Kandanelly RR, Solomon SD, Januzzi JL.
    Circ Heart Fail; 2021 Jun 15; 14(6):e008410. PubMed ID: 33998243
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.